Senesco Chooses VGXI to Produce Factor ...(any's licenseagreements; the acceptance ...),Health

Date:7/3/2008

any's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, our ability to maintain our continued listing standards for the next 12 months, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contacts: Investor Relations Contact:

Senesco Technologies, Inc. FD

Bruce Galton Brian Ritchie

Chief Executive Officer (brian.ritchie@fd.com)

(bgalton@senesco.com) (212) 850-5600

(732) 296-8400

VGXI, Inc.

Henry L. Hebel

Vice President of Operations

(hhebel@vgxii.com)

(281)-296-7300

'/>"/>

SOURCE Senesco Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
2. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
3. Senesco Technologies Initiates Preclinical Studies for Cancer Target
4. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
5. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
6. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
7. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
8. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
9. Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkins Lymphoma
10. R-CALF United Stockgrowers of America: Fighting for the U.S. Cattle Producer
11. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results